{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:01:31Z","timestamp":1790877691877,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T00:00:00Z","timestamp":1517961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Derivatives of hydrocortisone, such as mometasone furoate, a (2\u2032) furoate\u201017 ester with chlorine substitutions at positions 9 and 21, have been designed to improve efficacy and reduce the incidence of adverse effects. An extensive literature search of <jats:styled-content style=\"fixed-case\">MEDLINE<\/jats:styled-content>, Embase and other databases was conducted to review the safety and efficacy of various formulations of topical mometasone furoate. Mometasone furoate exhibits high potency with greater anti\u2010inflammatory activity and a longer duration of action than betamethasone. In clinical trials, mometasone furoate shows comparable or significantly better efficacy, depending on the comparator, in all indications studied in both adults and children. It is well tolerated with only transient, mild to moderate local adverse effects. It is characterised by low systemic availability due to its high lipophilicity, low percutaneous absorption and rapid hepatic biotransformation, and consequently has no significant effect on the hypothalamic\u2010pituitary\u2010adrenal axis. The molecular biotransformation of mometasone furoate in the skin results in a lower affinity with dermal cells than epidermal cells, which contributes to its low atrophogenicity. Sensitisation to mometasone furoate is low. Overall, mometasone furoate is a highly efficacious potent corticosteroid with a low risk of both local and systemic adverse effects.<\/jats:p>","DOI":"10.1111\/ajd.12762","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T05:46:41Z","timestamp":1517982401000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids"],"prefix":"10.1111","volume":"59","author":[{"given":"Fabrizio","family":"Spada","sequence":"first","affiliation":[{"name":"Ego Pharmaceuticals Braeside Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya M","family":"Barnes","sequence":"additional","affiliation":[{"name":"Ego Pharmaceuticals Braeside Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4717-3596","authenticated-orcid":false,"given":"Kerryn A","family":"Greive","sequence":"additional","affiliation":[{"name":"Ego Pharmaceuticals Braeside Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000049394"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.1991.tb00071.x"},{"key":"e_1_2_9_4_1","first-page":"94","article-title":"Clinical investigations of mometasone furoate \u2013 a novel, nonfluorinated, topical corticosteroid","volume":"6","author":"Medansky RS","year":"1987","journal-title":"Sem. Dermatol."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2013.063"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855010-00009"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12275"},{"key":"e_1_2_9_8_1","first-page":"184","article-title":"Mometasone furoate: a well\u2010established topical corticosteroid now with improved galenic formulations","volume":"4","author":"Molin S","year":"2013","journal-title":"J. Clin. Exp. Dermatol. Res."},{"key":"e_1_2_9_9_1","first-page":"394","article-title":"Percutaneous absorption of 0.1% mometasone furoate ointment fate, excretion and adrenocortical suppression","volume":"32","author":"Higashi N","year":"1990","journal-title":"Skin Res."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70224-H"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00192736"},{"key":"e_1_2_9_12_1","first-page":"25","article-title":"Comparison of the effect of mometasone furoate ointment 0.1% and hydrocortisone ointment 1% on adrenocortical function in psoriasis patients","volume":"5","author":"Bressinck R","year":"1988","journal-title":"Today's Ther. Trends"},{"key":"e_1_2_9_13_1","first-page":"67","article-title":"Continuous and intermittent treatment of atopic dermatitis in adults with mometasone furoate versus hydrocortisone 17\u2010butyrate","volume":"50","author":"H\u00f8ybye S","year":"1991","journal-title":"Curr. Ther. Res."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70092-G"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.1993.tb00040.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.1998.tb00713.x"},{"key":"e_1_2_9_17_1","first-page":"187","article-title":"In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new","volume":"33","author":"Kerscher MJ","year":"1995","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb08626.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1989.tb01361.x"},{"key":"e_1_2_9_20_1","unstructured":"Postmarking Safety Review PID D030565. Memorandum. Department of Health and Human Services. Centre for Drug Evaluation and Research. Available from URL:https:\/\/www.fda.gov\/ohrms\/...\/ac\/...\/3999B1_22_Karwoski-Memo%2009-26-03.DOC(Accessed 26 September 2003.)"},{"key":"e_1_2_9_21_1","first-page":"480","article-title":"Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent","volume":"42","author":"Medansky RS","year":"1988","journal-title":"Cutis"},{"key":"e_1_2_9_22_1","first-page":"92","article-title":"Efficacy and safety of mometasone furoate 0.1% once daily versus fluticasone propionate 0.005% twice daily in the management of psoriasis","volume":"15","author":"De Villez RL","year":"1998","journal-title":"Adv. Ther."},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(05)80413-8"},{"key":"e_1_2_9_24_1","first-page":"790","article-title":"A clinical investigation of the efficacy and safety of mometasone furoate ointment 0.1% vs betamethasone valerate ointment 0.1% in the treatment of psoriasis","volume":"44","author":"Rosenthal D","year":"1988","journal-title":"Curr. Ther. Res."},{"key":"e_1_2_9_25_1","first-page":"223","article-title":"Comparison of mometasone furoate 0.1% ointment and betamethasone dipropionate 0.05% ointment in the treatment of psoriasis vulgaris","volume":"8","author":"Peharda V","year":"2000","journal-title":"Acta Dermatovenerol. Croat."},{"key":"e_1_2_9_26_1","first-page":"X","article-title":"Comparative study of mometasone furoate and betamethasone dipropionate in the treatment of atopic dermatitis","volume":"129","author":"Marchesi E","year":"1994","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546639809160685"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546639209088705"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/030006059001800603"},{"key":"e_1_2_9_30_1","first-page":"203","article-title":"Mometasone versus betamethasone cream: a trial in dermatoses","volume":"26","author":"Wishart JM","year":"1993","journal-title":"N. Z. Med. J."},{"key":"e_1_2_9_31_1","first-page":"21","article-title":"Clinical study of mometasone furoate cream 0.1% compared to hydrocortisone butyrate cream 0.1% in treatment of atopic and seborrheic dermatitis","volume":"8","author":"Gip L","year":"1990","journal-title":"Today's Ther. Trends"},{"key":"e_1_2_9_32_1","first-page":"125","article-title":"Hydrocortisone butyrate 0.1% cream in the treatment of chronic dermatitis","volume":"75","author":"Fowler JF","year":"2005","journal-title":"Cutis"},{"key":"e_1_2_9_33_1","first-page":"341","article-title":"The therapeutic efficacy of mometasone furoate cream 0.1%, applied once daily vs clobetasol propionate cream 0.05% applied twice daily in chronic eczema","volume":"40","author":"Goh CL","year":"1999","journal-title":"Singapore Med. J."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1999.00759.x"},{"key":"e_1_2_9_35_1","first-page":"128","article-title":"Comparison of the safety and efficacy of mometasone furoate cream 0.1% and clobetasone butyrate cream 0.05% in the treatment of children with a variety of dermatoses","volume":"48","author":"Dominguez L","year":"1990","journal-title":"Curr. Ther. Res."},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02819.x"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2000.00099.x"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0033-4"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1159\/000335656"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1159\/000341809"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1989.tb02442.x"},{"key":"e_1_2_9_42_1","first-page":"145","article-title":"Clinical trial in scalp psoriasis mometasone furoate lotion 0.1% applied once daily vs betamethasone valerate lotion 0.1% applied twice daily","volume":"15","author":"Vanderploeg DE","year":"1989","journal-title":"Acta Ther."}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajd.12762","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.12762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T01:49:39Z","timestamp":1695001779000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajd.12762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1111\/ajd.12762"],"URL":"https:\/\/doi.org\/10.1111\/ajd.12762","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,7]]},"assertion":[{"value":"2017-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}